Eton Pharmaceuticals, Inc. $ETON Shares Newly Bought by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management initiated a 45,993-share position in Eton Pharmaceuticals valued at approximately $2.37 million, giving it about 0.16% ownership. Institutional investors collectively own 27.86% of the company.
• Eton reported quarterly earnings of $0.43 per share, exceeding the $0.19 analyst consensus, while revenue of $37.59 million also topped estimates. The stock opened at $50.00, with a market capitalization of approximately $1.43 billion.
• Analysts maintain a favorable outlook, with a consensus “Buy” rating and an average price target of $71.50. However, insiders sold 79,166 shares worth approximately $4.81 million over the past 90 days.

Robeco Institutional Asset Management B.V. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 45,993 shares of the company's stock, valued at approximately $2,368,000. Robeco Institutional Asset Management B.V. owned about 0.16% of Eton Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Toth Financial Advisory Corp purchased a new stake in shares of Eton Pharmaceuticals during the second quarter valued at approximately $43,000. USA Financial Formulas bought a new stake in shares of Eton Pharmaceuticals during the third quarter valued at approximately $62,000. Persistent Asset Partners Ltd purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $90,000. State of Wyoming purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $107,000. Finally, Quantbot Technologies LP purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $165,000. Institutional investors own 27.86% of the company's stock.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON opened at $50.00 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. Eton Pharmaceuticals, Inc. has a 12 month low of $14.27 and a 12 month high of $66.37. The company has a market cap of $1.43 billion, a PE ratio of 131.58 and a beta of 0.90. The company has a 50 day simple moving average of $56.92 and a two-hundred day simple moving average of $42.16.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to analyst estimates of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. Research analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. HC Wainwright reiterated a "buy" rating and set a $70.00 target price on shares of Eton Pharmaceuticals in a research note on Wednesday, October 14th. B. Riley Financial restated a "buy" rating and issued a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Weiss Ratings raised Eton Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a report on Tuesday, September 22nd. Zacks Research raised Eton Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 12th. Finally, Craig Hallum reaffirmed a "buy" rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Eton Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $71.50.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares of the company's stock, valued at $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Krempa sold 4,166 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the transaction, the insider directly owned 43,381 shares in the company, valued at approximately $2,388,991.67. This represents a 8.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 79,166 shares of company stock valued at $4,809,672 in the last ninety days. 16.49% of the stock is currently owned by corporate insiders.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton's commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.